Kamada Ltd. (KMDA)

Market Cap	442.16M
Revenue (ttm)	167.24M
Net Income (ttm)	16.06M
Shares Out	57.51M
EPS (ttm)	0.28
PE Ratio	27.53
Forward PE	22.00
Dividend	$0.20 (2.58%)
Ex-Dividend Date	Mar 17, 2025

Volume	60,451
Open	7.71
Previous Close	7.76
Day's Range	7.61 - 7.83
52-Week Range	4.93 - 9.16
Beta	0.13
Analysts	Strong Buy
Price Target	14.67 (+89.54%)
Earnings Date	Aug 13, 2025

About KMDA

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 420
• Stock Exchange: NASDAQ
• Ticker Symbol: KMDA
• Website: https://www.kamada.com

Financial Performance

In 2024, Kamada's revenue was $160.95 million, an increase of 12.93% compared to the previous year's $142.52 million. Earnings were $14.46 million, an increase of 74.58%.

Analyst Summary

According to 3 analysts, the average rating for KMDA stock is "Strong Buy." The 12-month stock price target is $14.67, which is an increase of 89.54% from the latest price.

Price Target

$14.67

(89.54% upside)

Analyst Consensus: Strong Buy